Profound Medical Corp. (PROF)

Profound Medical Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	3.26	2.44	0.39	2	3.15	4.58
Other Revenue	8.6	8.24	6.81	4.68	3.72	2.72
Revenue	11.86	10.68	7.2	6.68	6.87	7.3
Revenue Growth (YoY)	75.01%	48.35%	7.75%	-2.79%	-5.90%	74.99%
Cost of Revenue	3.84	3.64	2.89	3.66	3.92	3.83
Gross Profit	8.02	7.04	4.31	3.02	2.95	3.47
Selling, General & Admin	26.55	23.13	18.54	17.93	17.97	12.43
Research & Development	17.83	16.97	14.42	14.69	15.28	9.91
Operating Expenses	44.38	40.1	32.96	32.62	33.24	22.34
Operating Income	-36.35	-33.06	-28.65	-29.6	-30.29	-18.86
Interest Expense	-	-	-	-0.17	-0.07	-0.54
Interest & Investment Income	1.44	1.44	0.78	0.8	0.21	0.69
Currency Exchange Gain (Loss)	2.98	3.81	-0.58	3.1	-0.29	-2.54
Other Non Operating Income (Expenses)	-0.02	-	-	0.02	-0.16	-0.24
EBT Excluding Unusual Items	-31.96	-27.82	-28.45	-25.86	-30.59	-21.49
Impairment of Goodwill	-	-	-	-2.52	-	-
Other Unusual Items	-	-	-	-	-	-0.09
Pretax Income	-31.96	-27.82	-28.45	-28.38	-30.59	-21.58
Income Tax Expense	-0	-0	-0.13	0.29	0.11	0.05
Net Income	-31.96	-27.82	-28.32	-28.67	-30.7	-21.62
Net Income to Common	-31.96	-27.82	-28.32	-28.67	-30.7	-21.62
Shares Outstanding (Basic)	26	25	21	21	20	17
Shares Outstanding (Diluted)	26	25	21	21	20	17
Shares Change (YoY)	18.96%	16.91%	1.69%	1.79%	18.33%	55.83%
EPS (Basic)	-1.22	-1.12	-1.34	-1.38	-1.50	-1.25
EPS (Diluted)	-1.22	-1.12	-1.34	-1.38	-1.50	-1.25
Free Cash Flow	-27.21	-23.45	-22.61	-25.8	-22.39	-20.57
Free Cash Flow Per Share	-1.04	-0.95	-1.07	-1.24	-1.09	-1.19
Gross Margin	67.64%	65.89%	59.90%	45.22%	42.95%	47.56%
Operating Margin	-306.45%	-309.57%	-397.99%	-443.08%	-440.73%	-258.26%
Profit Margin	-269.39%	-260.45%	-393.43%	-429.11%	-446.66%	-296.03%
Free Cash Flow Margin	-229.36%	-219.60%	-314.06%	-386.17%	-325.80%	-281.68%
EBITDA	-35.5	-32.13	-27.72	-28.83	-29.61	-18.36
EBITDA Margin	-299.29%	-	-	-	-	-251.34%
D&A For EBITDA	0.85	0.94	0.93	0.78	0.68	0.51
EBIT	-36.35	-33.06	-28.65	-29.6	-30.29	-18.86
EBIT Margin	-	-	-	-	-	-258.26%
Revenue as Reported	11.86	10.68	7.2	6.68	6.87	7.3

Updated Mar 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q